Influence of frusemide on cis-dichlorodiammineplatinum (II) pharmaco-kinetics

Cis-dichlorodiammineplatinum (CDDP) pharmacokinetics were evaluated in eighteen patients with cancer who received 80 mg/m2 CDDP as a 20 min infusion. One hour before, 10 of them had 20 mg/m2 frusemide. Fifteen blood samples and fifteen urine samples were collected over the 5 hours following the infu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of drug metabolism and pharmacokinetics 1987-07, Vol.12 (3), p.203-206
Hauptverfasser:	DUMAS, M, D'ATHIS, P, DE GISLAIN, C, LAUTISSIER, J. L, AUTISSIER, N, ESCOUSSE, A, GUERRIN, J
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Biological and medical sciences Cisplatin - pharmacokinetics Furosemide - pharmacology General aspects Humans Kidney Diseases - metabolism Medical sciences Pharmacology. Drug treatments Platinum - blood Platinum - urine Spectrophotometry, Atomic
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Cis-dichlorodiammineplatinum (CDDP) pharmacokinetics were evaluated in eighteen patients with cancer who received 80 mg/m2 CDDP as a 20 min infusion. One hour before, 10 of them had 20 mg/m2 frusemide. Fifteen blood samples and fifteen urine samples were collected over the 5 hours following the infusion of CDDP. Platinum was assayed by flameless atomic absorption. The data did not detect any difference between patients with or without frusemide for the following platinum parameters: plasma concentration, urinary concentration, cumulative urinary excretion, renal clearance. These results suggest that frusemide has no influence upon cisplatin (CDDP) pharmacokinetics and if it protects the kidneys, it is not via kinetic modifications.
ISSN:	0378-7966 2107-0180
DOI:	10.1007/BF03189898